Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Impact analysis of rotavirus vaccination in various geographic regions in Western Europe

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Self-reported immunity and opinions on vaccination of hospital personnel among paediatric healthcare workers in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Are refugees arriving in Denmark an under-immunised group for measles? A cross-sectional serology study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The malaria parasite Plasmodium falciparum presents antigens on the infected erythrocyte surface that bind human receptors expressed on the vascular endothelium. The VAR2CSA mediated binding to a distinct chondroitin sulphate A (CSA) is a crucial step in the pathophysiology of placental malaria and the CSA binding region of VAR2CSA has been identified as a promising vaccine target against placental malaria. Here we designed adenovirus encoded virus-like particles (VLP) by co-encoding Simian Immunodeficiency Virus (SIV) gag and VAR2CSA. The VAR2CSA antigen was fused to the transmembrane (TM) and cytoplasmic tail (CT) domains of either the envelope protein of mouse mammary tumour virus (MMTV) or the hemagglutinin (HA) of influenza A. For a non-VLP incorporation control, a third design was made where VAR2CSA was expressed without TM-CT domains. In the primary immunogenicity study in Balb/c mice, VAR2CSA fused to HA TM-CT was significantly superior in inducing ID1-ID2a specific antibodies after the first immunization. A sequential study was performed to include a comparison to the soluble VAR2CSA protein vaccine, which has entered a phase I clinical trial (NCT02647489). The results revealed the induction of higher antibody responses and increased inhibition of parasite binding to CSA using either VAR2CSA HA TM-CT or VAR2CSA MMTV TM-CT as priming vaccines for protein double-boost immunizations, compared to protein prime-double boost regimen. Analysis of pooled serum samples on peptide arrays revealed a unique targeting of several epitopes in mice that had been primed with VAR2CSA HA TM-CT. Consequently, modification of VLP anchors is an important point of optimization in virus-encoded retroviral VLP-based vaccines, and adenovirus VLPs boosted by recombinant proteins offer hope of increasing the levels of protective VAR2CSA specific antibodies.

Original languageEnglish
JournalVaccine
Volume35
Issue number8
Pages (from-to)1140-1147
Number of pages8
ISSN0264-410X
DOIs
Publication statusPublished - 22 Feb 2017

    Research areas

  • Adenoviridae, Animals, Antibodies, Protozoan, Antigens, Protozoan, Chondroitin Sulfates, Erythrocytes, Female, Gene Products, gag, Genetic Vectors, Hemagglutinin Glycoproteins, Influenza Virus, Humans, Immunization, Malaria Vaccines, Malaria, Falciparum, Mammary Tumor Virus, Mouse, Mice, Mice, Inbred BALB C, Placenta, Plasmodium falciparum, Pregnancy, Protein Binding, Recombinant Fusion Proteins, Simian Immunodeficiency Virus, Vaccines, Virus-Like Particle, Journal Article, Research Support, Non-U.S. Gov't

ID: 52820189